[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2408807T3 - Fremgangsmåde til terapeutisk anvendelse - Google Patents

Fremgangsmåde til terapeutisk anvendelse Download PDF

Info

Publication number
DK2408807T3
DK2408807T3 DK10710017.4T DK10710017T DK2408807T3 DK 2408807 T3 DK2408807 T3 DK 2408807T3 DK 10710017 T DK10710017 T DK 10710017T DK 2408807 T3 DK2408807 T3 DK 2408807T3
Authority
DK
Denmark
Prior art keywords
therapeutic use
therapeutic
Prior art date
Application number
DK10710017.4T
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Maria Pihlgren
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Application granted granted Critical
Publication of DK2408807T3 publication Critical patent/DK2408807T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
DK10710017.4T 2009-03-18 2010-03-18 Fremgangsmåde til terapeutisk anvendelse DK2408807T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16116509P 2009-03-18 2009-03-18
US25602809P 2009-10-29 2009-10-29
PCT/EP2010/053519 WO2010106127A2 (en) 2009-03-18 2010-03-18 Method for therapeutic use

Publications (1)

Publication Number Publication Date
DK2408807T3 true DK2408807T3 (da) 2021-08-09

Family

ID=42376556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10710017.4T DK2408807T3 (da) 2009-03-18 2010-03-18 Fremgangsmåde til terapeutisk anvendelse

Country Status (17)

Country Link
US (1) US20100285108A1 (da)
EP (2) EP2408807B1 (da)
JP (2) JP2012520852A (da)
KR (1) KR20120004994A (da)
CN (1) CN102428101B (da)
AU (1) AU2010224824B2 (da)
CA (1) CA2755683A1 (da)
DK (1) DK2408807T3 (da)
ES (1) ES2885398T3 (da)
HU (1) HUE055739T2 (da)
IL (1) IL214919A (da)
MX (1) MX2011009654A (da)
PT (1) PT2408807T (da)
RU (1) RU2579659C2 (da)
SG (1) SG174871A1 (da)
SI (1) SI2408807T1 (da)
WO (1) WO2010106127A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス.エー. タウを認識するリン酸化部位特異的抗体
KR102129220B1 (ko) * 2011-09-23 2020-07-02 에이씨 이뮨 에스.에이. 백신 요법
KR101981351B1 (ko) * 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス.エー. ヒト化タウ抗体
CN104428411B (zh) * 2012-05-08 2018-11-23 健康科学西部大学 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台
KR102233349B1 (ko) 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
ES2852001T3 (es) 2015-01-23 2021-09-10 Helix Biopharma Corp Conjugados de anticuerpo-ureasa para propósitos terapéuticos
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
EP3700556A2 (en) * 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
US11684576B2 (en) 2019-02-08 2023-06-27 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
WO2024156908A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Liposomal construct

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
JP2004503747A (ja) * 2000-07-11 2004-02-05 モレキュラー ジェリアトリクス コーポレイション 結合物質の同定するための試薬と方法
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1494000A1 (en) * 2003-07-02 2005-01-05 Sicpa Holding S.A. Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
JP4934433B2 (ja) * 2004-02-20 2012-05-16 エーシー イミューン ソシエテ アノニム 超分子コンストラクトを含む方法および組成物
KR101236611B1 (ko) * 2005-12-12 2013-03-04 에이씨 이뮨 에스.에이. 치료 백신
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція

Also Published As

Publication number Publication date
MX2011009654A (es) 2011-10-12
HUE055739T2 (hu) 2021-12-28
AU2010224824A2 (en) 2011-09-22
JP2012520852A (ja) 2012-09-10
ES2885398T3 (es) 2021-12-13
EP3978517A1 (en) 2022-04-06
CN102428101B (zh) 2016-03-02
AU2010224824A1 (en) 2011-09-22
RU2011141889A (ru) 2013-04-27
CA2755683A1 (en) 2010-09-23
JP2015221809A (ja) 2015-12-10
IL214919A (en) 2016-10-31
WO2010106127A3 (en) 2011-03-31
SI2408807T1 (sl) 2021-11-30
WO2010106127A2 (en) 2010-09-23
AU2010224824B2 (en) 2014-02-20
RU2579659C2 (ru) 2016-04-10
IL214919A0 (en) 2011-11-30
EP2408807B1 (en) 2021-07-21
PT2408807T (pt) 2021-09-03
CN102428101A (zh) 2012-04-25
KR20120004994A (ko) 2012-01-13
EP2408807A2 (en) 2012-01-25
US20100285108A1 (en) 2010-11-11
SG174871A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
CY2017047I1 (el) Συνδυαστικη θεραπεια για χαπ
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
BR112012015988A2 (pt) método
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
BRPI1012526A2 (pt) método
BRPI1010705A2 (pt) método
BRPI0917684A2 (pt) método terapêutico homeopático
DK2310613T3 (da) Forbedret brudled til stigrør
DK2513288T3 (da) Indretning til kontinuerlig dyrkning
BRPI1012532A2 (pt) método
BR112013009024A2 (pt) método
BR112012023891A2 (pt) método
BRPI1009350A2 (pt) método
ITPD20090053U1 (it) Paradordi per banchine
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BR112013015580A2 (pt) método de radioestabilização
BR112012033000A2 (pt) método
ES1070798Y (es) Ataud
DK2404510T3 (da) Indretning til temperering
TH105556B (th) สารประกอบ และ วิธีการใหม่สำหรับการบำบัด
IT1396653B1 (it) Apparato
IT1396965B1 (it) Dispositivo terapeutico